> Details

R, Saravanan.; T, Somanathan.; D, Gavaskar.; V, Sriraman.; M, Tamilvanan.

Development and Validation of Stability Indicating Related Substances Method for Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate (DLT) Tablets using High Performance Liquid Chromatography

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Development and Validation of Stability Indicating Related Substances Method for Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate (DLT) Tablets using High Performance Liquid Chromatography
  • Contributor: R, Saravanan.; T, Somanathan.; D, Gavaskar.; V, Sriraman.; M, Tamilvanan.
  • Published: A and V Publications, 2022
  • Published in: Research Journal of Pharmacy and Technology (2022), Seite 2147-2150
  • Language: English
  • DOI: 10.52711/0974-360x.2022.00356
  • ISSN: 0974-360X; 0974-3618
  • Keywords: Pharmacology (medical) ; Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Origination:
  • Footnote:
  • Description: A novel, accurate, specific, linear, precise and robust RP-HPLC method (stability indicating) has been developed and validated for the related substances (impurities) analysis of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate in tablet formulation. This research paper presents the developed method and the outcome of validation challenges. The RP-HPLC method was developed on a 250 x 4.6 mm, 5 µm, C18 column, with a gradient mode using combination of phosphate buffer and phosphoric acid in methanol and water as mobile phase, the detection was performed at 265nm and 235nm. The method was subjected to validation challenges of specificity, precision, linearity, accuracy, robustness and is demonstrated to be suitable for testing of stability samples.
  • Access State: Open Access